The richest man starts with black technology

"Nature" is one of the most authoritative academic journals in the world, and it is considered by many scientific and technological workers to be one of the highest halls of academic papers.

Many influential industries and scientific research results are usually favored by Nature.

Middle's logic is very simple. He heard that Origin Technology's paper on symbiotic proteins had been submitted to Nature, but Nature did not have a bird paper, let alone published it.

If the symbiotic photosynthetic green leaf protein is really realized, and it can really change the course of biomedicine, there is no reason why Nature should not be published.

After interviewing Middle and others, the New York Times reported on the absurd scam of symbiotic photosynthetic green leaf protein under the headline "Technology is not science fiction.

There are two basis for this report in the New York Times.

One was an on-site interview with Huaxi Hospital and found that many patients with lung diseases were still waiting there, and did not receive the so-called symbiotic bacteria treatment.

"The New York Times" certainly cannot interview patients who have already received treatment, because these patients are still in the observation period and will not be interviewed by reporters at all.In addition, the production of symbiotic bacilli is not large, and it cannot satisfy a large number of patients to receive treatment.

The second is that the international mainstream academia scoffed at the technology of symbiotic photosynthetic green leaf protein, and even bothered to comment.In Xia Guo, only one third-rate academic journal published this paper, which shows that the technology is not reliable.

Like the "New York Times" and other Western media's long-term reports on Xia Guo's prejudice, this article cost most of the Western independent chat after dinner.

However, the report in the Chinese version of the "New York Times" is different. The title becomes "A large number of patients waiting for treatment with new technology", and the content is also very neutral, like the description of Zhang San going to Li Sijia for dinner.

Look, the media has to do well.

In addition to the "New York Times", many science and technology columnists are also writing articles to criticize the illusion of symbiotic proteins.

After all, everybody needs to have a good meal, and symbiotic protein is a rare topic at the moment. Who else would you write about?

Zhou Xiao has no time to chat, nor to read the New York Times report.

Technology products: symbiotic photosynthetic green leaf protein.Monopoly value, city 17.3%; disgust value, city 3.2%.

Symbiotic proteins have formed a wide range of influence in the domestic medical community. Until the scale of treatment is expanded, the monopoly value will not increase much.

The current monopoly value is much higher than the disgust value, Zhou Xiao's choice is also very simple, continue to expand the influence of this technology.

It can not only cure diseases and save people, but also increase monopoly value and make money. This is also a win-win-win choice.

The final cost of symbiotic protein treatment is also calculated.

Chen Hao drove from the factory to the headquarters with a stack of documents and reported to Zhou Xiao.

Chen Hao has become the team leader of the life science laboratory and has realized his life value.

He now recalled what Zhou Xiao said when he first joined Origin Technology. As expected, not a single word was fart, and all came true.

Chen Hao handed the information to Zhou Xiao and said: "Zhou, if you don't count the initial investment, only the cost of the production, storage, and transportation of symbiotic bacteria is calculated, which is about 400 yuan per cubic centimeter."

Chen Hao added: “Because our production line is limited now, all the strains cannot get effective profits. In the future, the cost of the new technology zone will be greatly reduced after the plant is completed.”

Zhou Xiao estimated the cost, 400 yuan a cubic centimeter, based on ordinary people transplanting 200 to 300 square centimeters, the cost of a treatment cost 80,000 to 120,000, which is the cost price of Origin Technology.

Zhou Xiao not only calculates costs, but also calculates profits.

Origin Technology must not be conscientious to make money for domestic patients, but before large-scale mass production, it must be 20% higher than the cost to maintain the normal operation of the company and subsequent increase in production, expansion and scientific research.

What's more, Origin Technology still has a huge initial investment, and this investment has to be slowly recovered.

In this way, the price is 480 yuan per cubic centimeter, and the total cost is about 96,000 to 144,000.

The cost of treatment for patients in the hospital will increase, and the cost should be around 200,000.

Two hundred thousand, all depends on the patient's own expense.

For patients with a better family background, 200,000 can be fully afforded, which is not a problem at all.

But how many of those patients suffering from pneumoconiosis and interstitial pneumonia have good family conditions?

According to official statistics, there are about 6 million patients with pneumoconiosis in Xia Guo.

Most of these 6 million are low-level workers, engaged in high-dust, high-polluting industries, and with meager salaries. The money has to support the family. It is difficult to take 20,000 yuan. Where can there be 200,000 yuan for treatment.

Zhou Xiao frowned, pacing back and forth in the office.

If the patient cannot afford the cost, the treatment technology of symbiotic protein cannot be covered and promoted.

This is not a question of making money or not, but a question of failing to complete the task if the monopoly value cannot meet the requirements.

If the panel keeps stuck in the symbiotic protein, Zhou Xiao will be wrong!often!Do not!open!heart!

How can the technology be able to be widely used by patients and to prevent Origin Technology from losing money? This is a question.

The way Zhou Xiao can think of is crowdfunding!

Mobilizing the resources of the society to help patients, this can not only reduce the burden on patients but also make the treatment technology popular.

Crowdfunding requires cooperation with some disease crowdfunding treatment companies and even insurance companies to allow the other party to include symbiotic treatment in the scope of crowdfunding treatment, but it depends on whether the other party has relevant intentions.

When Origin Technology contacted some crowdfunding platform companies, President Peng of the People's Court of Jiangcheng found Zhou Xiao.

Because of the establishment of the Oasis Hair Transplant Center, the income and influence of Jiangcheng People's Hospital have increased a lot.

But as a general hospital, why is President Peng willing to turn Jiangcheng People's Hospital into a pure hair transplant center?

Jiangcheng People's Hospital and Origin Technology have cooperated for a long time. Now that Origin Technology puts the revolutionary treatment technology of symbiotic protein in Huaxi Hospital in Rongcheng instead of Jiangcheng Hospital, he is not happy.

This time I came to visit in person, hoping to create a more professional respiratory medicine department.

The reasons given by Dean Peng are also very convincing, "Jiangcheng City's old industrial city, in terms of the number of pneumoconiosis patients, Jiangcheng ranked top, let the patients go to Rongcheng for the treatment headquarters in front of their homes, okay?"

Zhou Xiao is ashamed. There are many pneumoconiosis patients worth bragging about?

Zhou Xiao originally planned to expand the scope of the symbiotic protein treatment. Of course, he was willing to cooperate with Jiangcheng People's Hospital and also proposed his own cooperation plan.

Jiangcheng People's Hospital and Origin Technology jointly established a respiratory medicine treatment center.

The center is under the jurisdiction of the hospital. Origin Technology provides products and dispatches technical instructors to guide doctors in treatment.

The main purpose of Zhou Xiao's dispatch of technicians is to try adjuvant therapy for lung cancer patients, in addition to guidance. This part is still a gap in current clinical trials.

But when Zhou Xiao paid out the cost of the symbiotic protein treatment, Dean Peng was really embarrassed.

"It costs 200,000 yuan for the treatment. The symbiotic protein has just been in clinical treatment and has not been included in medical insurance. The patient pays more than 200,000 yuan... I am afraid that many people will not be able to afford it."

At this moment, Wang Yulan returned the news.

Several large crowdfunding platforms have stated that pneumoconiosis, interstitial pneumonia, lung cancer, etc. are all within the scope of crowdfunding, and they don't care how the hospital treats them.

But here comes the problem again. Crowdfunding takes time and requires various harsh terms (repost times, exposure time, etc.).

For patients who are in a race against life, I am afraid that if the money is not enough, there will be no people.

Besides, those workers living at the bottom may not be able to use smartphones, let alone what crowdfunding is.

Peng Yufei also felt that it would be unreliable if all hopes for the treatment were placed on crowdfunding.

The two were thinking of a way.